INOVIO PHARMACEUTICALS, INC. Foreign Currency Transaction Gain (Loss), before Tax
INOVIO PHARMACEUTICALS, INC. (INO) reported Foreign Currency Transaction Gain (Loss), before Tax of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-06.
Discontinued › Income Statement › Other Income
us-gaap:ForeignCurrencyTransactionGainLossBeforeTax · last filed 2024-03-06
- INOVIO PHARMACEUTICALS, INC. foreign currency transaction gain (loss), before tax for the quarter ending 2022-12-31 was $0.00.
- INOVIO PHARMACEUTICALS, INC. foreign currency transaction gain (loss), before tax for the quarter ending 2022-09-30 was $0.00.
- INOVIO PHARMACEUTICALS, INC. foreign currency transaction gain (loss), before tax for the quarter ending 2022-06-30 was $0.00.
- INOVIO PHARMACEUTICALS, INC. foreign currency transaction gain (loss), before tax for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- INOVIO PHARMACEUTICALS, INC. foreign currency transaction gain (loss), before tax for fiscal 2023 was $0.00.
- INOVIO PHARMACEUTICALS, INC. foreign currency transaction gain (loss), before tax for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- INOVIO PHARMACEUTICALS, INC. foreign currency transaction gain (loss), before tax for fiscal 2021 was $176.93K.
- INOVIO PHARMACEUTICALS, INC. foreign currency transaction gain (loss), before tax for fiscal 2020 was -$15.90K.
| Period end | Foreign Currency Transaction Gain (Loss), before Tax 3 month | Foreign Currency Transaction Gain (Loss), before Tax 6 month | Foreign Currency Transaction Gain (Loss), before Tax 9 month | Foreign Currency Transaction Gain (Loss), before Tax 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-03-06 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $0.00 derived: sum of 2 quarters · filed 2024-03-06 | $0.00 derived: sum of 3 quarters · filed 2024-03-06 | $0.00 10-K · filed 2024-03-06 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $0.00 derived: sum of 2 quarters · filed 2022-11-08 | $0.00 10-Q · filed 2022-11-08 | $0.00 derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $0.00 10-Q · filed 2022-08-09 | $0.00 derived: sum of 3 quarters · filed 2024-03-06 | $0.00 derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-10 | $0.00 derived: sum of 2 quarters · filed 2024-03-06 | $0.00 derived: sum of 3 quarters · filed 2024-03-06 | $0.00 derived: sum of 4 quarters · filed 2024-03-06 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $0.00 derived: sum of 2 quarters · filed 2024-03-06 | $0.00 derived: sum of 3 quarters · filed 2024-03-06 | $176.93K 10-K · filed 2024-03-06 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $0.00 derived: sum of 2 quarters · filed 2022-11-08 | $176.93K 10-Q · filed 2022-11-08 | -$129.58K derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $176.93K 10-Q · filed 2022-08-09 | -$129.58K derived: sum of 3 quarters · filed 2023-03-01 | -$313.05K derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $176.93K 10-Q · filed 2022-05-10 | -$129.58K derived: sum of 2 quarters · filed 2023-03-01 | -$313.05K derived: sum of 3 quarters · filed 2023-03-01 | -$520.13K derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | -$306.50K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | -$489.97K derived: sum of 2 quarters · filed 2023-03-01 | -$697.05K derived: sum of 3 quarters · filed 2023-03-01 | -$15.90K 10-K · filed 2023-03-01 |
| 2020-09-30 | -$183.47K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$390.55K derived: sum of 2 quarters · filed 2021-11-09 | $290.60K 10-Q · filed 2021-11-09 | $3.19K derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | -$207.08K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $474.07K 10-Q · filed 2021-08-09 | $186.66K derived: sum of 3 quarters · filed 2022-03-01 | $2.90K derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $681.15K 10-Q · filed 2021-05-10 | $393.74K derived: sum of 2 quarters · filed 2022-03-01 | $209.98K derived: sum of 3 quarters · filed 2022-03-01 | |
| 2019-12-31 | -$287.42K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$471.17K derived: sum of 2 quarters · filed 2022-03-01 | -$471.17K 10-K · filed 2022-03-01 | |
| 2019-09-30 | -$183.76K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$183.76K 10-Q · filed 2020-11-09 | ||
| 2019-06-30 | $0.00 10-Q · filed 2020-08-10 | |||
| 2018-12-31 | $0.00 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |